Researcher.Life Logo

Ophthalmology and Therapy : Impact Factor & More

eISSN: 2193-6528pISSN: 2193-8245
JournalOpen Access

Key Metrics

CiteScore
4.8
Impact Factor
< 5
SJR
Q1Ophthalmology
SNIP
1.7
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Ophthalmology and Therapy

Ophthalmology and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER INT PUBL AG
Language English
Frequency Semi-annual
Article Processing ChargesEUR 5500 | USD 6850 | GBP 4700
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencySemi-annual
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Ophthalmology and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Ophthalmology and Therapy

Summary of Research: Economic Benefit of Aflibercept 8mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.
  • 20 May 2026
  • Ophthalmology and therapy
Half-Dose Photodynamic Therapy for Bullous Variant Central Serous Chorioretinopathy: A Long-Term Follow-Up.
  • 19 May 2026
  • Ophthalmology and therapy
Prospective Real-World Outcomes After Switching to Aflibercept 8mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden.
  • 19 May 2026
  • Ophthalmology and therapy
The Role of Sex in Ocular Biometry: A Large-Scale Study of Cataract Candidates in Greece.
  • 16 May 2026
  • Ophthalmology and therapy
Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.
  • 15 May 2026
  • Ophthalmology and therapy
A Multicenter, Real-World Experience with Polyhexamethylene Biguanide (PHMB) 0.08% Monotherapy for Treating Acanthamoeba Keratitis: A Retrospective Review of 39 Cases.
  • 15 May 2026
  • Ophthalmology and therapy
Summary of Research: Economic Benefit of Aflibercept 8mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.
  • 20 May 2026
  • Ophthalmology and therapy
Half-Dose Photodynamic Therapy for Bullous Variant Central Serous Chorioretinopathy: A Long-Term Follow-Up.
  • 19 May 2026
  • Ophthalmology and therapy
Prospective Real-World Outcomes After Switching to Aflibercept 8mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden.
  • 19 May 2026
  • Ophthalmology and therapy
The Role of Sex in Ocular Biometry: A Large-Scale Study of Cataract Candidates in Greece.
  • 16 May 2026
  • Ophthalmology and therapy
Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.
  • 15 May 2026
  • Ophthalmology and therapy
A Multicenter, Real-World Experience with Polyhexamethylene Biguanide (PHMB) 0.08% Monotherapy for Treating Acanthamoeba Keratitis: A Retrospective Review of 39 Cases.
  • 15 May 2026
  • Ophthalmology and therapy

FAQs on Ophthalmology and Therapy